AVXL
Income statement / Annual
Last year (2023), Anavex Life Sciences Corp.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Anavex Life Sciences Corp.'s net income was -$47.51 M.
See Anavex Life Sciences Corp.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
09/30/2015 |
09/30/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1,252.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$1,252.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$43.72 M
|
$37.92 M
|
$32.98 M
|
$25.23 M
|
$22.26 M
|
$13.34 M
|
$10.67 M
|
$7.25 M
|
$2.27 M
|
$732,395.00
|
| General & Administrative
Expenses |
$12.04 M
|
$13.07 M
|
$9.02 M
|
$5.86 M
|
$6.85 M
|
$5.99 M
|
$5.01 M
|
$8.33 M
|
$4.84 M
|
$2.24 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$12.04 M
|
$13.07 M
|
$9.02 M
|
$5.86 M
|
$6.85 M
|
$5.99 M
|
$5.01 M
|
$8.33 M
|
$4.84 M
|
$2.24 M
|
| Other Expenses |
$0.00 |
$3.32 M |
-$54,100.00 |
-$149,888.00 |
-$298,943.00 |
$1.63 M |
$2.02 M |
$151,402.00 |
$0.00 |
$199,655.00 |
| Operating Expenses |
$55.76 M |
$50.99 M |
$41.95 M |
$30.94 M |
$28.81 M |
$19.18 M |
$15.54 M |
$14.88 M |
$7.11 M |
$2.97 M |
| Cost And Expenses |
$55.76 M |
$50.99 M |
$41.95 M |
$30.94 M |
$28.81 M |
$19.18 M |
$15.54 M |
$14.88 M |
$7.11 M |
$2.97 M |
| Interest Income |
$6.52 M |
$946,988.00 |
$26,261.00 |
$179,973.00 |
$207,280.00 |
$255,092.00 |
$88,098.00 |
$11,322.00 |
$0.00 |
$0.00 |
| Interest Expense |
$964,000.00 |
$946,988.00 |
$0.00 |
$0.00 |
$151,133.00 |
$0.00 |
$0.00 |
$11.32 M |
$71,825.00 |
$7,089.00 |
| Depreciation &
Amortization |
-$2.72 M
|
-$3.32 M
|
$37.46 M
|
$26.71 M
|
$26.64 M
|
$17.50 M
|
$1,252.00
|
$1,252.00
|
$995.00
|
$768.00
|
| EBITDA |
-$55.76 M
|
-$50.94 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$15.57 M
|
-$15.02 M
|
-$7.11 M
|
-$2.97 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$8.26 M
|
$3.37 M
|
$4.36 M
|
$4.83 M
|
$3.08 M
|
$2.10 M
|
$2.28 M
|
$881,960.00
|
-$5.00 M
|
-$8.40 M
|
| Income Before Tax |
-$47.50 M |
-$47.62 M |
-$37.64 M |
-$26.26 M |
-$26.21 M |
-$17.38 M |
-$13.40 M |
-$14.71 M |
-$12.11 M |
-$11.37 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$7,000.00 |
$358,492.00 |
$267,565.00 |
$22,664.00 |
$82,181.00 |
$72,746.00 |
$59,607.00 |
$29,615.00 |
$71,825.00 |
$7,089.00 |
| Net Income |
-$47.51 M |
-$47.98 M |
-$37.91 M |
-$26.28 M |
-$26.29 M |
-$17.45 M |
-$13.46 M |
-$14.74 M |
-$12.11 M |
-$11.37 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.6 |
-0.62 |
-0.54 |
-0.45 |
-0.54 |
-0.39 |
-0.33 |
-0.42 |
-0.65 |
-1.16 |
| EPS Diluted |
-0.6 |
-0.62 |
-0.54 |
-0.45 |
-0.54 |
-0.39 |
-0.33 |
-0.42 |
-0.65 |
-1.16 |
| Weighted Average Shares
Out |
$79.79 M
|
$76.91 M
|
$69.80 M
|
$58.19 M
|
$48.91 M
|
$44.66 M
|
$40.84 M
|
$35.15 M
|
$18.58 M
|
$9.80 M
|
| Weighted Average Shares
Out Diluted |
$79.79 M
|
$76.91 M
|
$69.80 M
|
$58.19 M
|
$48.91 M
|
$44.66 M
|
$40.84 M
|
$35.15 M
|
$18.58 M
|
$9.80 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
